university website

Lellouche, J. (J.), Schwartz, D. (D.), Elmalech, N. (N.), Ben Dalak, M.A. (M. A.), Temkin, E. (E.), M. Paul (Mical), Geffen, Y. (Y.), Yahav, D. (D.), Eliakim-Raz, N. (N.), E. Durante-Mangoni (Emanuele), et al. Iossa, D. (D.), Bernardo, M. (M.), G.L. Daikos (George), Skiada, A. (A.), Pantazatou, A. (A.), A. Antoniadou (A.), J.W. Mouton (Johan), Y. Carmeli (Yehuda), Nutman, A. (A.), Cohen-Percia, S. (S.), Daitch, V. (V.), Babich, T. (T.), Andini, R. (R.), Cuccurullo, S. (S.), Cristinziano, A. (A.), Cavezza, G. (G.), Bertolino, L. (L.), Giuffrè, G. (G.), Giurazza, R. (R.), Mallardo, E. (E.) and Zampino, R. (R.)

2018-10-04

Combining VITEK® 2 with colistin agar dilution screening assist timely reporting of colistin susceptibility

Publication

Publication

Clinical Microbiology and Infection

Objectives: The rise in carbapenem resistance among Gram-negative bacteria has renewed interest in colistin. Recently, the EUCAST-CLSI Polymyxin Breakpoints Working Group declared that broth microdilution (BMD) is the only valid method for colistin susceptibility testing. BMD is not easily incorporated into the routine work of clinical laboratories, and usually this test is incorporated serially, resulting in delayed susceptibility reporting. We tested a strategy of combining VITEK® 2 with a 2 μg/mL colistin agar dilution (VITEK® 2/AD) screening plate to improve performance and time to reporting of colistin susceptibility.
Methods: Colistin susceptibility for 364 clinical isolates was determined by VITEK® 2/AD and compared with the reference standard BMD according to the ISO 20776-1:2007 and CLSI guidelines. The EUCAST colistin susceptibility breakpoint of ≤2 μg/mL was used. Escherichia coli NCTC 13846 served as quality control strain. Agreement, very major error (VME) and major error rates were determined using ISO 20776-2:2007.
Results: The VME rate for VITEK® 2 alone was 30.6% (15/49, 95% CI 18.3–45.4%), and was reduced to 10.2% (5/49, 95% CI 3.4–22.2%) using the VITEK® 2/AD combined testing. The combined testing had categorical agreement with BMD of 97% (354/364, 95% CI 95.0–98.7%), and a major error (ME) rate of 1.6% (5/315, 95% CI 0.5–3.7%). Using the combined testing, even against challenging strains, 349 (95.8%, 95% CI 93.3–97.7%) colistin susceptibility results could be reported, and only 15 isolates required further analysis by BMD.
Discussion: Our method is simple to apply and allows rapid reporting of colistin susceptibility.

Additional Metadata
Keywords Agar dilution, Broth microdilution, Carbapenem resistance, Colistin susceptibility, Combined method, VITEK 2
Persistent URL doi.org/10.1016/j.cmi.2018.09.014, hdl.handle.net/1765/111914
Journal Clinical Microbiology and Infection
Grant This work was funded by the European Commission 7th Framework Programme; grant id fp7/278348 - Preserving old antibiotics for the future : assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for off-patent antibiotics (AIDA)
Organisation Department of Medical Microbiology and Infectious Diseases
Citation
Lellouche, J. (J.), Schwartz, D. (D.), Elmalech, N. (N.), Ben Dalak, M.A. (M. A.), Temkin, E. (E.), Paul, M., … Zampino, R. (R.). (2018). Combining VITEK® 2 with colistin agar dilution screening assist timely reporting of colistin susceptibility. Clinical Microbiology and Infection. doi:10.1016/j.cmi.2018.09.014


User Publication Person Organisation Collection
Close